Neuropsychopharmacology
July 24, 2023
John H. Krystal, Ege T Kavalali, Lisa M Monteggia
229 citations
Ketamine is an open channel blocker of ionotropic glutamatergic N -Methyl- D -Aspartate (NMDA) receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression fostered novel effective treatments for mood disorders. This discovery not only provided new insight into the neurobiology of mood disorders but also uncovered fundamental...
Behavioural Brain Research
July 22, 2023
Merve Akan, Ivan Skorodumov, M. Meinhardt et al.
The delayed onset of monoaminergic antidepressants and disadvantages of traditional administration routes created the need for alternative non-invasive delivery methods with rapid onset therapeutic effect. Ketamine attracted attention as a fast-acting glutamatergic antidepressant with ideal physiochemical properties for alternative routes of administration. However, there is no sufficient data...
Scientific Reports
July 19, 2023
Adelaida Castillo, Julien Dubois, Ryan M. Field et al.
19 citations
Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind,...
Neuropsychiatric Disease and Treatment
July 17, 2023
Cheng-Chuan Chen, Xiao-Bin Wang
Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide. In contrast, as the only drug approved by the FDA,...
Pharmaceuticals
July 17, 2023
Glorister A. Altê, Ana Lúcia S Rodrigues
17 citations
Ketamine, a racemic mixture of esketamine (S-ketamine) and arketamine (R-ketamine), has received particular attention for its rapid antidepressant and antisuicidal effects. NMDA receptor inhibition has been indicated as one of the main mechanisms of action of the racemic mixture, but other pharmacological targets have also been proposed. This study aimed to explore the possible multiple targets...
The British Journal of Psychiatry
July 14, 2023
Colleen Loo, N. Glozier, David Barton et al.
70 citations
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed. Aims To assess the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au. Method This phase 3,...
Neuropsychiatric Disease and Treatment
July 12, 2023
Lucian Manu
Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis." This letter is not a rebuttal to the article but, rather, a response to further clarify a few points on the real-world use of ketamine and esketamine.
International Clinical Psychopharmacology
July 11, 2023
Lucas Arrighi, Eloïse Maakaron, Théo Korchia et al.
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD...
Frontiers in Neuroscience
July 11, 2023
Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Mariusz S. Wiglusz et al.
8 citations
Background: Psychotic treatment-resistant depression represents a complex and challenging form of mood disorder in clinical practice. Despite its severity, psychotic depression is frequently underdiagnosed and inadequately treated. Ketamine has demonstrated rapid and potent antidepressant effects in clinical studies, while exhibiting a favorable safety and tolerability profile. Although there...
International Clinical Psychopharmacology
July 7, 2023
Nicola Ragone, Barbara Barbini, Carolina Passani et al.
More than 10 years ago, the discovery of the antidepressant effects of Ketamine opened the opportunity to develop a novel class of antidepressants. Ketamine induces dissociative symptoms as a major side effect. This rapid-acting antidepressant is available as an endovenous racemic compound and as an intranasal S-enantiomer: Esketamine; which is four-fold more potent for the NMDA receptor. Here...